Abstract Number: 0298 • ACR Convergence 2023
Accuracy of the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criteria and Myositis-Specific Autoantibodies-Based Classification Criteria for Classifying Patients with Idiopathic Inflammatory Myopathy
Background/Purpose: Limitations of the 2017 EULAR/ACR classification criteria have been suggested for classifying patients with idiopathic inflammatory myopathies (IIMs) and myositis-specific antibodies (MSAs). On this…Abstract Number: 1948 • ACR Convergence 2023
The Influence of Specific Myositis Antibodies on the Development of Interstitial Lung Disease
Background/Purpose: Interstitial Lung Disease (ILD), prevalent in Idiopathic Inflammatory Myositis (IIM) patients, significantly impacts prognosis. Certain myositis-specific antibodies, including anti-MDA5 and anti-aminoacyl-tRNA synthetases (ARS), are…Abstract Number: 2580 • ACR Convergence 2023
High-intensity Resistance Training Improves Quality of Life, Muscle Endurance and Strength in Patients with Myositis
Background/Purpose: Myositis is associated with muscle impairment, which impacts quality of life. The purpose of this study was to investigate the effects of high-intensity strength…Abstract Number: 100 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools
Background/Purpose: Muscle weakness is often progressive and persistent in Juvenile Dermatomyositis (JDM). Muscle strength testing is useful for evaluating severity of muscle weakness. There is…Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…Abstract Number: 1871 • ACR Convergence 2022
Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample…Abstract Number: 1877 • ACR Convergence 2022
Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a non-invasive tool used to evaluate the microcirculation of patients with connective tissue diseases (CTDs). A specific combination of NVC…Abstract Number: 0156 • ACR Convergence 2022
Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database
Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are systemic autoimmune diseases of inflammatory infiltrates in skeletal muscle resulting in chronic muscle weakness. Systemic involvement of the…Abstract Number: 1882 • ACR Convergence 2022
Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogenous group of acquired autoimmune diseases characterised by inflammation of muscle and affection of other organs, including lung…Abstract Number: 0164 • ACR Convergence 2022
Anti-SSa/SSb and Ro52 Status and Pulmonary Function Tests in Patients with Interstitial Lung Disease and Idiopathic Inflammatory Myopathies
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with idiopathic inflammatory myositis (IIM). Anti-SSa/SSb and Ro52 are frequently…Abstract Number: 1884 • ACR Convergence 2022
Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska
Background/Purpose: Racial disparities have been in noted in various autoimmune disorders. Indigenous North American populations have higher prevalence and severity of a number of autoimmune…Abstract Number: 0166 • ACR Convergence 2022
Detection of the Novel Autoantibodies Against Transcription Factor Sp4 Is Related with Low Risk of Cancer in Idiopathic Inflammatory Myopathy Patients
Background/Purpose: In idiopathic inflammatory myopathy (IIM), many kinds of autoantibodies are often detected and associated with each clinical phenotype. Recently, autoantibody against transcription factor Sp4…Abstract Number: 1886 • ACR Convergence 2022
Statin-induced Immune-mediated Miopathy: Treatment with Glucocorticoid-free Protocols and Role of Muscle Biopsy in the Follow-up
Background/Purpose: Statin-induced immune mediated necrotizing myopathy (IMNM) is a recently identified autoimmune condition associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies, characterized by progressive muscle weakness leading…Abstract Number: 0171 • ACR Convergence 2022
Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare disorders that can affect the heart. It is unclear which patients are at higher risk.…Abstract Number: 2237 • ACR Convergence 2022
Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods
Background/Purpose: A 52-week (wk), randomized, placebo (PBO)-controlled phase 3 trial of subcutaneous (SC) abatacept (ABA) and standard of care (SOC) was performed in patients (pts)…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »